UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 12, 2011

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

California	**001-14758**	**33-0476164**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

1300 Kellogg Drive, Suite D, Anaheim, California	**92807**
(Address of Principal Executive Offices)	**(Zip Code)**

Registrant's telephone number, including area code: **(714) 786-4200**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Commencing on December 12, 2011, Questcor Pharmaceuticals, Inc. (the "Company") will utilize an updated presentation for investor relations purposes. The presentation includes the following update regarding prescription information for the Company's primary product, H.P. Acthar Gel (repository corticotropin injection) ("Acthar") for the first two months of the quarter ending December 31, 2011, based on the most recent data available to the Company at the time of this filing:

- For acute exacerbations of multiple sclerosis ("MS"), the number of new, paid prescriptions was between 615 and 625 for the time period between October 1, 2011 through November 30, 2011.
- For nephrotic syndrome ("NS"), the number of new, paid prescriptions was between 83 and 87 for the time period between October 1, 2011 through November 30, 2011.
- For infantile spasms ("IS"), the number of new, paid prescriptions was between 88 and 92 for the time period between October 1, 2011 through November 30, 2011, which is above the Company's normal historic range for a two month period.

The Company is also disclosing the following unaudited balance sheet information as of December 7, 2011:

- Cash, cash equivalents and short-term investments: $209 million.
- Accounts receivable: $27 million

Risk Factor Regarding Volatility of Prescription Levels

The number of new, paid prescriptions for Acthar in each therapeutic area is volatile and the Company cautions investors to not view data for a single month or a single quarter as representative of a trend or otherwise being predictive of future results. **For example, the month of September 2011 experienced high levels of prescriptions for MS and NS and, as such, it is unclear how the number of new, paid prescriptions in MS and NS for the full fourth quarter ending December 31, 2011 will compare to the full third quarter ended September 30, 2011.** The Company believes that investors should consider the Company's results over several quarters when analyzing the Company's performance. In addition, December has a significant number of holidays which may cause disruption in our selling effort and impact sales.

Important, Previously Disclosed Information Regarding Prescriptions and Net Sales

Net sales of Acthar are derived from the Company's sales of vials to CuraScript Specialty Distributor ("CuraScript SD"), which in turn sells Acthar primarily to specialty pharmacies. These specialty pharmacies place orders to CuraScript SD based on their respective levels of sales and inventory practices. End-user demand for Acthar results from physicians writing prescriptions to patients for the treatment of MS exacerbations, NS, IS and various other conditions. Recommended treatment regimens among physicians prescribing Acthar vary within each therapeutic area. Due to various factors, including inventory levels at both the specialty pharmacies and at CuraScript SD, the duration of treatment regimens and the timing of the placement of refill prescription orders, there is typically a delay between changes in prescription levels and changes in the levels of orders the Company receives from CuraScript SD. Additionally, treatment regimens, and patient compliance with physician-recommended treatment regimens, may vary over time.

The Company's ability to accurately determine the number of prescriptions is subject to the following important notes:

(1) Because Acthar prescriptions are filled at specialty pharmacies, the Company does not receive complete information regarding either the number of prescriptions or the number of vials by therapeutic area for all of the patients being treated with Acthar. However, the Company is able to monitor trends in payer mix and areas of therapeutic use for new (non-refill) Acthar prescriptions based on data the Company receives from its reimbursement support center. The Company estimates that over 90% of new Acthar prescriptions are processed by this support center, but believes that very few refill prescriptions are processed there.

(2) Prescription figures include related conditions for each therapeutic area. Related conditions are diagnoses that are either alternative descriptions of the medical condition or are closely related to the medical condition referenced above. For example, a prescription for "Demyelinating disease of the central nervous system" would be included as an MS-related condition for purpose of the updated prescription information provided above. About 5% of the prescriptions referenced for a specific indication are for related conditions.

(3) A new prescription may or may not represent a new patient or a new therapy for the patient receiving the prescription. The Company uses business rules to determine whether a prescription should be classified as new for counting purposes. From time to time, the Company may modify these rules.

Note Regarding Future Release of Information

The Company currently intends to release additional information regarding key performance metrics for the fourth quarter ending December 31, 2011 on or about January 9, 2012, before the J. P. Morgan Healthcare Conference. It is the Company's current intent to continue the practice of releasing key performance metrics between regular quarterly earnings releases in conjunction with presentations that the Company makes at investor conferences that feature webcasts.

The presentation is furnished under this Item 7.01 pursuant to Regulation FD and is included as Exhibit 99.1 to this Current Report on Form 8-K. The presentation will also be made available on the Company's website at www.questcor.com. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	***Description***
99.1	Presentation made by Questcor Pharmaceuticals, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 12, 2011

QUESTCOR PHARMACEUTICALS, INC.

By: /s/ MICHAEL MULROY

Michael Mulroy, Chief Financial Officer & General Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation made by Questcor Pharmaceuticals, Inc.

NASDAQ:QCOR

December 2011

QUESTCOR®

Safe Harbor Statement

Note: Except for the historical information contained herein, this presentation contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "should," "substantial," "trends" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following: our reliance on Acthar for substantially all of our net sales and profits; reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations; the complex nature of our manufacturing process and the potential for supply disruptions or other business disruptions; the lack of patent protection for Acthar, and the possible FDA approval and market introduction of competitive products; our ability to generate revenue from sales of Acthar to treat on-label indications associated with nephrotic syndrome, and our ability to develop other therapeutic uses for Acthar including systemic lupus erythematosus; research and development risks, including risks associated with our work in the area of nephrotic syndrome and potential work in the area of systemic lupus erythematosus, and our reliance on third-parties to conduct research and development and the ability of research and development to generate successful results; regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits; our ability to receive high reimbursement levels from third party payers; an increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities; our ability to estimate reserves required for Acthar used by government entities and Medicaid-eligible patients and the impact that unforeseen invoicing of historical Medicaid prescriptions may have upon our results; our ability to operate within an industry that is highly regulated at both the Federal and state level; our ability to effectively manage our growth, including the expansion of our nephrotic syndrome selling effort, and our reliance on key personnel; the impact to our business caused by economic conditions; our ability to protect our proprietary rights; our ability to maintain effective controls over financial reporting; the risk of product liability lawsuits; unforeseen business interruptions; volatility in our monthly and quarterly Acthar shipments and end-user demand, as well as volatility in our stock price; and other risks discussed in our annual report on Form 10-K for the year ended December 31, 2010, and other documents filed with the Securities and Exchange Commission.

The risk factors and other information contained in these documents should be considered in evaluating our prospects and future financial performance.

QUESTCOR®

Questcor

A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions

QUESTCOR®

Questcor Overview

Flagship Product: H.P. Acthar® GEL (repository corticotropin injection) 80 U/mL

- 19 approved indications

Key Markets:

- Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms
- Combined market opportunity exceeds $1.5 billion

Strategy:

- Grow Acthar sales in each key market
- Develop on-label Lupus markets for Acthar

Financials:

- Profitable, cash flow positive, $209M* in cash, debt-free

QUESTCOR®

* As of 12/7/11

History of Acthar



QUESTCOR®

Significant Barriers to Entry



QUESTCOR®

QCOR Strategy – Sell More Acthar

- Multiple Sclerosis (MS)
- Nephrotic Syndrome (NS)
- Infantile Spasms (IS)
- Systemic Lupus Erythematosus

QUESTCOR®

Acthar and MS

- Neurodegenerative disorder
- Acute treatment for relapses
- Treatment for 1-2 weeks*
- $40K-$50K/Rx



QUESTCOR®

*Based on prescriptions written

MS Scripts-Record of Consistent Growth

Yellow numbers in the bars show the number of MS sales people making calls at the end of the quarter.

New Paid Rxs

QUESTCOR®

Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart.

Monthly MS Scripts Have 160% CAGR

QUESTCOR®

Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart.

MS Trends

- **Doubled sales force: 38 to 77 sales reps Nov 2010**
- **Q3-2011 results**
  - **Q3-11 new, paid Rxs up 174% vs. Q3-10**
  - **MS about 65% of QCOR net sales***
    - **Estimated $150M annualized run-rate***
  - **About 450 prescribers in Q3**
  - **September was a record month**
- **October-November 2011**
  - **615-625 new, paid Rxs**
  - **Holiday season might impact prescription trends**

QUESTCOR®

*Based on Company estimates as of 9/30/11

Acthar and Nephrotic Syndrome (N

- Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria)
- Can result in end-stage renal disease (ESRD), dialysis, transplant
- Significant unmet need
  - Few treatment options
- Treatment for 4-6+ months*
  - Longer course of therapy creates future vial demand
- $150K-250K/Rx

QUESTCOR®

*Based on prescriptions written

NS Scripts Off to a Good Start



Yellow numbers in the bars show the number of NS sales people making calls at the end of the quarter. Q3' 11 included expansion and training of new sales people.

New Paid Rxs

QUESTCOR®

Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart.

NS Market Size

- Idiopathic membranous nephropathy
- FSGS
- IgA nephropathy
- Minimal change disease
- Lupus nephritis
- **Estimated total: 20,000-25,000 patients**

QUESTCOR®

NS Trends

- Initiated sales efforts in early March 2011
  - Q1 2011 new, paid NS Rxs: 18
  - Q2 2011 new, paid NS Rxs: 45
  - Q3 2011 new, paid NS Rxs: 60
- Expanded NS selling effort: 5 to 28 NS during Q3
- Planned sales calls to increase in Q4 by 7X over Q2
- October-November 2011
  - 83-87 new, paid Rxs
  - Holiday season might impact prescription trends

QUESTCOR®

NS Phase IV Company Sponsored Study

- **Treatment Resistant Idiopathic Membranous Nephropathy**
- **Dose response trial**
  - **Randomized, double blinded 3 arm study with 2 different dosage regimens of Acthar and placebo**
  - **n=84 (approximate), 35 centers (approximate)**
  - **Endpoint is reduction of proteinuria**
- **Trial milestones**
  - **"First look" data available early 2013**
  - **Final reporting late 2013**

QUESTCOR®

Infantile Spasms

- Devastating, refractory form of childhood epilepsy
  - Very poor developmental outcome if inadequately treated
- Not responsive to standard anti-epileptic drugs
- Ultra-rare orphan disorder
  - 1,500 to 2,000 patients annually
- Typically occurs in children less than 2 years old
- Characterized by
  - "spasms" a specific type of seizure
  - "hypsarrhythmia" abnormal EEG pattern

QUESTCOR®

Acthar and IS

- FDA approval 10/15/10
- Crisis therapy
- Treatment for 2-4 weeks*
- In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks versus 29% on prednisone
- $100K-$125K/Rx
  - About half of patients receive drug for free

QUESTCOR®

*Based on prescriptions written

IS Trends

- Acthar currently used to treat 40-50% of IS patients
- Targeting select institutions
  - Promotion effort being narrowed as market is maturing
  - Creates selling time for Acthar MS reps to target NS
- Significant variability in quarterly Rxs
- Q3-2011 new, paid Rxs within historic range
- October-November 2011
  - 88-92 new, paid Rxs
  - New, paid Rxs above historic range

QUESTCOR®

Total Acthar Sales Force

- **Specialty Sales Force**
  - Main focus on MS (time split is ~ 80%/15%/5% on MS/NS/IS)
  - 77 representatives, 13 regional managers, one national director
- **Nephrology Sales Force**
  - Focus 100% on Nephrotic Syndrome
  - 28 representatives, 4 regional managers, one national director
- **Combined Forces targeted to call on**
  - >4,000 neurologists
  - >3,000 nephrologists
  - About 100 key children's hospitals

QUESTCOR®

Immediate Actha r Growth Opportunities

MS	NS	IS
• Build on sales momentum, good market headroom • Market size- $500M+	• Significantly expanded selling effort to 28 reps during Q3 • Market size- $1B+	• Targeted sales strategy • Market size- $100M

QUESTCOR®

*Represents estimated net sales market opportunity based on internal company estimates

Systemic Lupus Erythematosus (Lupus)

- High unmet need
- Serious health risk if unsuccessfully treated
- Difficult to treat
- Multiple on-label indications for Acthar
  - Exacerbations
  - Maintenance therapy
  - Lupus nephritis
- Large patient population

QUESTCOR®

Financials

- Profitable
- Debt Free
- Cash Flow Positive

QUESTCOR®

Q3-2011 Financial Results

Record Net Sales (up 91%) and Solid Earnings (EPS up 94%)

	Q3-2011	Q3-2010
Net Sales ($M)	**$59.8**	$31.3
Gross Margin	**94%**	93%
Operating Income ($M)	**$33.6**	$16.8
Fully Diluted, GAAP EPS	**$0.35**	$0.18

- Third quarter vials shipped: 2,910
- Third quarter cash flow from operations: $32.6M
- Channel inventory estimated to be within historic range
- Medicaid reserves continue to appear adequate
- No shares repurchased

QUESTCOR®

Questcor is Cash Flow Positive

	12/7/11
Cash / ST Investments	**$209M***
Accounts Receivable	**$27M**

*After return of $78 million of cash to shareholders through share repurchases.

Debt-free balance sheet

QUESTCOR®

Share Repurchases: 15 Million Sha

- 2.2 Million Preferred share buyback
- 13.2 Common share buyback
- $78 million returned to shareholders in stock buybacks
- 63.6 million shares currently outstanding
- 4.3 million shares remain on buyback authorization

Repurchased shares significantly improved EPS

QUESTCOR®

Go Forward Plan – Sell More Acthar

- **Sustain effort and momentum with MS**
- **Sustain effort and momentum with NS**
- **Maintain and gradually grow IS sales**
- **Explore Systemic Lupus Erythematosus (Lupus) as another vertical market**
- **Develop other markets for Acthar**
  - **Acthar is its own pipeline with many other on-label and many possible other therapeutic uses**
  - **Further define and develop the unique characteristics of Acthar**
- **No business development efforts planned**

QUESTCOR®

Investment Highlights

- Acthar has sustainable competitive advantages- without FDA approval risk
- Acthar is approved for 19 indications-many in large markets with sizable unmet need
- Sales in MS and NS are growing rapidly, yet market penetration is low
- Developing new vertical market — Lupus
- High margins provide good operating leverage
- Profitable, cash flow positive, no debt

QUESTCOR®


NASDAQ:QCOR
December 2011
QUESTCOR®